Local application of FFR-rFVIIa reduces thrombus formation at arterial anastomosis in rats.
Thrombosis is still a significant problem in microvascular surgery. The aim of this study was to evaluate the antithrombotic effect of topically applied active site-inhibited recombinant human factor VIIa (FFR-rFVIIa) in a rat model with microvascular thrombosis. Forty-five male rats were allocated to one of three groups: local treatment with vehicle only, local treatment with 0.035 mg of FFR-rFVIIa, or local treatment with 0.35 mg of FFR-rFVIIa. An arteriotomy was made in the right femoral artery. Ten minutes following topical application, a thrombogenic anastomosis was performed. Using a transilluminator, thrombus formation and anastomotic bleeding episodes were observed and registered for 40 min. Local application of FFR-rFVIIa resulted in a 85-90% reduction of thrombus formation in both treated groups compared to the control group, but the reduction was only statistically significant in the group treated with 0.035 mg of FFR-rFVIIa. An increased occurrence and duration of anastomotic bleeding episodes were observed in both FFR-rFVIIa-treated groups.
Sørensen
H B
HB
Department of Plastic Surgery, Arhus University Hospital, Denmark.
Kristensen
A T
AT
Ravn
H B
HB
Fuglsang
J
J
Hjortdal
V E
VE
D000287:Administration, Topical; D000818:Animals; D001163:Arteriovenous Anastomosis; D005167:Factor VII / Q000008:administration & dosage* / Q000627:therapeutic use; D015942:Factor VIIa; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008866:Microsurgery; D019106:Postoperative Hemorrhage / Q000209:etiology; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa